Lys-Glu dipeptide studied as a thymic/immune bioregulator
PRODUCT PROFILE
Vilon
£46.00
Vilon is lys-glu dipeptide studied as a thymic/immune bioregulator. Researchers examine it in relation to immune-cell differentiation and gene-expression hypotheses.
Why it is distinct
A minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
- Evidence stageExperimental
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Vilon is lys-glu dipeptide studied as a thymic/immune bioregulator. Researchers examine it in relation to immune-cell differentiation and gene-expression hypotheses.
Research focus+
Researchers study possible effects on immune-cell development and gene activity. Evidence is limited and it is not an established immune treatment.
How the mechanism differs+
Proposed to modulate immune-related gene transcription, but a specific validated receptor is not established.
Evidence and limitations+
Limited regional preclinical and small human literature; independent replication is sparse.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study possible effects on immune-cell development and gene activity. Evidence is limited and it is not an established immune treatment.
Proposed to modulate immune-related gene transcription, but a specific validated receptor is not established.
A minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
Limited regional preclinical and small human literature; independent replication is sparse.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Bronchogen
£46.0020 mgBatch file pendingAirway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.
UnavailableAsk about availability -
Early human evidence
LL-37
£59.005 mgBatch file pendingDirect antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
UnavailableAsk about availability -
Established
Thymosin Alpha-1
£69.0010 mgBatch file pendingAn immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
UnavailableAsk about availability -
Clinical research
VIP
Price range: £29.99 through £38.995 mgBatch file pendingA receptor-defined pleiotropic neuropeptide with direct vasodilatory and bronchodilatory effects.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page